Table 1. Baseline characteristics of COVID-19 patients who presented unfavorable outcomes (ventilation support need and death) and those who did not.
| No VS | VS | p value | Discharge | Death | p value | |
|---|---|---|---|---|---|---|
| (n = 106) | (n = 12) | (n = 96) | (n = 23) | |||
| Mean ± SD or % | Mean ± SD or % | Mean ± SD or % | Mean ± SD or % | |||
| Males (%) | 44.3 | 66.7 | ns | 44.8 | 52.2 | ns |
| Age (y) | 71.9 ± 14.6 | 64.8 ± 13.6 | 0.08 | 69.6 ± 14.4 | 77.5 ± 13.1 | 0.01 |
| COMORBIDITIES | ||||||
| T2D (%) | 21.7 | 0 | nc | 19.8 | 17.4 | ns |
| Hypertension (%) | 47.2 | 41.7 | ns | 46.9 | 47.8 | ns |
| Underweight (%) | 11.3 | 8.3 | ns | 6.3 | 27.2 | 0.005 |
| Overweight (%) | 31.8 | 25 | ns | 36.7 | 13.6 | 0.005 |
| Obese (%) | 17.1 | 25 | ns | 20.3 | 9.1 | 0.01 |
| CVD (%) | 29.3 | 41.7 | ns | 29.1 | 34.8 | ns |
| Respiratory diseases (%) | 14.1 | 0 | nc | 12.5 | 13.0 | ns |
| CNS Disease (%) | 16.0 | 0 | nc | 11.5 | 26.1 | 0.07 |
| Malignancy (%) | 23.6 | 25.0 | ns | 18.8 | 43.5 | 0.01 |
| CKD (%) | 12.8 | 8.3 | ns | 9.4 | 21.7 | 0.09 |
| CONCOMITANT THERAPIES | ||||||
| Metformin (%) | 13.9 | 0 | nc | 13.1 | 11.7 | ns |
| Insulin (%) | 1.1 | 0 | nc | 1.2 | 0 | ns |
| Acetyilsalicylic acid (%) | 32.3 | 25.0 | ns | 31.0 | 33.3 | ns |
| Oral anticoagulants (%) | 16.1 | 0 | nc | 14.3 | 16.7 | ns |
| Beta-blockers (%) | 26.9 | 28.6 | ns | 26.2 | 29.4 | ns |
| ACEi/ARB (%) | 34.4 | 42.9 | ns | 36.9 | 23.5 | ns |
| Diuretics (%) | 35.5 | 14.3 | ns | 33.3 | 35.3 | ns |
| Statins (%) | 25.8 | 28.6 | ns | 22.6 | 47.1 | 0.03 |
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CNS, central nervous system; CVD, cardiovascular disease; ns, not significant; SD, standard deviation; T2D, type 2 diabetes; VS, ventilation support.